Arcturus Therapeutics
Total Raised
$15.22MInvestors Count
4Deal Terms
1Funding, Valuation & Revenue
8 Fundings
Arcturus Therapeutics has raised $15.22M over 8 rounds.
Arcturus Therapeutics's latest funding round was a PIPE for on September 26, 2023.
Arcturus Therapeutics's 2020 revenue was $9.54M. Arcturus Therapeutics's most recent revenue is from 2020.
Sign up for a free demo to see revenue data from 2023 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
9/26/2023 | PIPE | 2 | ||||
6/19/2019 | Corporate Minority - P2P | $9.54M FY 2020 | ||||
9/28/2017 | Reverse Merger | |||||
5/31/2017 | Grant | |||||
10/27/2015 | Debt |
Date | 9/26/2023 | 6/19/2019 | 9/28/2017 | 5/31/2017 | 10/27/2015 |
|---|---|---|---|---|---|
Round | PIPE | Corporate Minority - P2P | Reverse Merger | Grant | Debt |
Amount | |||||
Investors | |||||
Valuation | |||||
Revenue | $9.54M FY 2020 | ||||
Sources | 2 |
Arcturus Therapeutics Deal Terms
1 Deal Term
Arcturus Therapeutics's deal structure is available for 1 funding round, including their Series A from October 21, 2013.
Round | Series A |
|---|---|
Funding Date | |
Pre-Money Valuation | |
Post-Money Valuation | |
Amount Raised | |
Shares Authorized | |
Issuance Price | |
Dividend Rate | |
Liquidation Preferences | |
Liquidation Price | |
Participation | |
Conversion Price | |
Anti Dilution | |
General Voting | |
Board Voting | |
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series A |
Arcturus Therapeutics Investors
4 Investors
Arcturus Therapeutics has 4 investors. Cystic Fibrosis Foundation invested in Arcturus Therapeutics's PIPE funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
5/31/2017 | 9/26/2023 | 2 Grant, PIPE (2023) | Non-Profit Foundation | Maryland | ||
Corporation | California | |||||
Corporation | Israel | |||||
Incubator/Accelerator | California |
First funding | 5/31/2017 | |||
|---|---|---|---|---|
Last Funding | 9/26/2023 | |||
Investor | ||||
Rounds | 2 Grant, PIPE (2023) | |||
Board Seats | ||||
Type | Non-Profit Foundation | Corporation | Corporation | Incubator/Accelerator |
Location | Maryland | California | Israel | California |
Compare Arcturus Therapeutics to Competitors
ReCode Therapeutics is a clinical-stage company that develops therapeutics for rare diseases within the biotechnology sector. The company utilizes its SORT lipid nanoparticle platform for the delivery of mRNA and gene correction therapies to various organs and tissues. ReCode Therapeutics serves the healthcare sector, specifically addressing rare and genetically defined diseases. It was founded in 2015 and is based in Menlo Park, California.
VaxEquity develops RNA-based therapeutics and vaccines designed to meet medical needs. It specializes in amplifying the impact of RNA vaccines and therapeutics by using its self-amplifying RNA platform and provides better protein expression. The company was founded in 2020 and is based in Cambridge, U.K.
Harness Therapeutics operates as a biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases. The company specializes in messenger ribonucleic acid (mRNA)-targeted oligonucleotide-based methodologies to increase protein levels in a controlled manner. It aims to transform the treatment of conditions such as Alzheimer's, Parkinson's, and Huntington's disease. Harness Therapeutics primarily serves the healthcare sector. It was formerly known as Transine Therapeutics. Harness Therapeutics was founded in 2018 and is based in Cambridge, United Kingdom.
Versameb focuses on the discovery and development of ribonucleic acid (RNA) based drugs. The company provides solutions for modulating protein expression and influencing therapeutic targets using a molecular construct. Versameb's VERSagile technology platform supports the application of functional RNA in different disease contexts to expand the use of RNA therapeutics. It was founded in 2017 and is based in Basel, Switzerland.
Strand Therapeutics specializes in the development of programmable mRNA therapeutics within the biotechnology sector. The company's main offerings include long-acting mRNA therapies that utilize logic-based circuits to enable control over the location, timing, intensity, and duration of protein expression. Strand Therapeutics primarily targets the healthcare sector, focusing on solutions for cancer and other serious diseases. It was founded in 2017 and is based in Boston, Massachusetts.
Arbor Biotechnologies operates as a gene editing company in the biotechnology sector, focusing on gene editing. The company specializes in the discovery and development of genomic medicines for patients with genetic diseases. Arbor Biotechnologies uses genomic editors to create targeted therapies for different diseases. It was founded in 2016 and is based in Cambridge, Massachusetts.
Loading...